Research Analysts’ Recent Ratings Changes for argenex (ARGX)

A number of research firms have changed their ratings and price targets for argenex (NASDAQ: ARGX):

• 9/6/2026 – argenex was upgraded by Wall Street Zen from “hold” to “buy”.
• 9/3/2026 – argenex had its “outperform” rating reaffirmed by Wedbush. They now have a $1,150.00 price target on the stock.
• 8/31/2026 – argenex had its price target raised by Morgan Stanley from $1,230.00 to $1,250.00. They now have an “overweight” rating on the stock.
• 8/29/2026 – argenex was upgraded by Wall Street Zen from “hold” to “buy”.
• 8/26/2026 – argenex had its price target raised by Wells Fargo & Company from $1,350.00 to $1,415.00. They now have an “overweight” rating on the stock.
• 8/26/2026 – argenex was upgraded by UBS Group AG from “neutral” to “buy”. They now have a $1,400.00 price target on the stock, up from $960.00.
• 8/24/2026 – argenex was downgraded by Deutsche Bank Aktiengesellschaft from “buy” to “hold”.
• 8/18/2026 – argenex had its price target raised by Truist Financial Corporation from $1,030.00 to $1,095.00. They now have a “buy” rating on the stock.
• 8/18/2026 – argenex had its price target raised by Morgan Stanley from $1,200.00 to $1,230.00. They now have an “overweight” rating on the stock.
• 8/18/2026 – argenex had its price target raised by Royal Bank Of Canada from $1,025.00 to $1,100.00. They now have an “outperform” rating on the stock.
• 8/18/2026 – argenex had its price target raised by Wedbush from $1,050.00 to $1,150.00. They now have an “outperform” rating on the stock.
• 8/18/2026 – argenex had its price target raised by Citizens Jmp from $932.00 to $1,200.00. They now have a “market outperform” rating on the stock.
• 8/18/2026 – argenex had its price target raised by HC Wainwright from $940.00 to $1,202.00. They now have a “buy” rating on the stock.
• 8/17/2026 – argenex had its price target raised by Piper Sandler from $1,075.00 to $1,215.00. They now have an “overweight” rating on the stock.
• 8/15/2026 – argenex was downgraded by Wall Street Zen from “buy” to “hold”.
• 8/4/2026 – argenex is now covered by Guggenheim. They set a “buy” rating and a $1,185.00 price target on the stock.
• 7/28/2026 – argenex had its price target raised by Wedbush from $1,000.00 to $1,050.00. They now have an “outperform” rating on the stock.
• 7/27/2026 – argenex had its price target raised by Robert W. Baird from $867.00 to $932.00. They now have a “neutral” rating on the stock.
• 7/25/2026 – argenex was upgraded by Wall Street Zen from “hold” to “buy”.
• 7/24/2026 – argenex had its price target raised by Oppenheimer Holdings, Inc. from $1,014.00 to $1,037.00. They now have an “outperform” rating on the stock.
• 7/24/2026 – argenex had its price target raised by Royal Bank Of Canada from $945.00 to $1,025.00. They now have an “outperform” rating on the stock.
• 7/24/2026 – argenex had its price target raised by Guggenheim from $1,135.00 to $1,185.00. They now have a “buy” rating on the stock.
• 7/24/2026 – argenex had its price target lowered by Citizens Jmp from $944.00 to $932.00. They now have a “market outperform” rating on the stock.
• 7/23/2026 – argenex was downgraded by Weiss Ratings from “hold (c+)” to “hold (c)”.
• 7/21/2026 – argenex had its price target raised by Citigroup Inc. from $1,152.00 to $1,182.00. They now have a “buy” rating on the stock.

argenx SE is a global biopharmaceutical company focused on developing and commercializing antibody-based medicines for patients with severe autoimmune diseases. The company’s research is centered on its antibody engineering technologies, including the SIMPLE Antibody platform and NHance technology, which are designed to identify and enhance therapeutic antibodies.

argenx’s leading product is VYVGART (efgartigimod alfa), an antibody fragment that targets the neonatal Fc receptor, or FcRn, to reduce disease-causing immunoglobulin G antibodies.